Cervical Intraepithelial Neoplasia
A malignancy arising in uterine cervical epithelium and confined thereto, representing a continuum of histological changes ranging from well-differentiated CIN 1 (formerly, mild dysplasia) to severe dysplasia/carcinoma in situ, CIN 3. The lesion arises at the squamocolumnar cell junction at the transformation zone of the endocervical canal, with a variable tendency to develop invasive epidermoid carcinoma, a tendency that is enhanced by concomitant human papillomaviral infection. (Segen, Dictionary of Modern Medicine, 1992)
Drugs by status
Phase 4 trials (8)
Phase 3 trials (4)
Phase 2 trials (26)
- aminolevulinic acid
- urea
- black raspberry
- bls_ilb_710c
- bls_ils_e710c
- progesterone
- paclitaxel
- l-glutamic acid
- gx-188e
- artesunate
- pembrolizumab
- pemetrexed
- pepcan
- ro5217790
- tetra-o-methyl nordihydroguaiaretic acid
- vgx-3100
- ondansetron
- vvax001
- hexose
- sivifene
- hexyl 5-aminolevulinate
- aprepitant
- HPV16-E7-T512
- mva-hpv
- chadox1-hpv
- abi-2280
Phase 1 trials (15)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (29)
- Meda
- Eisai
- Roche
- Inovio Pharmaceuticals
- Shanghai Zerun Biotechnology Co.,Ltd
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- United States Navy
- Maastricht University
- Medical University of Graz
- Albert Schweitzer Hospital
- Cornell University
- Meander Medical Center
- Medical University Innsbruck
- New York University
- Sint Franciscus Gasthuis
- University of Salzburg
- Xiamen University
- University of Vienna
- University of Kinshasa
- Krankenhaus der Barmherzigen Schwestern Linz
- Government of China
- University of Texas at Houston
- Erasmus University Rotterdam
- New York Presbyterian Hospital
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- University of Antwerp
- Chinese Academy of Medical Sciences
- Azienda USL Nord Ovest
Organization Involved with Phase 2 Indications (71)
- DFB Pharma
- Advaxis, Inc.
- Eli Lilly
- BioLeaders Corporation
- Catalysis SL
- Erimos Pharmaceuticals
- Mithra Pharmaceuticals
- Photocure
- Shanghai Zhangjiang Biotechnology Limited Company
- Theradex
- Kirax
- Vaccibody AS
- Genexine, Inc.
- Planned Parenthood
- The University of Texas Health Science Center, Houston
- Aarhus University
- University of Arizona
- University of Pittsburgh
- Augusta University
- Harvard University
- East Tallinn Central Hospital
- Georgetown University
- Gottfried Wilhelm Leibniz Universität Hannover
- Gynecologic Oncology Group
- Hoosier Cancer Research Network
- Jersey Shore University Medical Center
- Johns Hopkins University
- Korea University
- Odessa National Medical University
- University of Maryland
- +41 more
Organization Involved with Phase 1 Indications (12)
- Nventa Biopharmaceuticals Corporation
- HealthBanks Biotech Co., Ltd.
- Preventive Oncology International, Inc.
- Huazhong University of Science and Technology
- University of Pennsylvania
- Baylor University
- Emory University
- University of Rochester
- Instituto Nacional de Enfermadades Neoplasticas (INEN)
- Shenzhen University
- Peru Instituto Nacional de Enfermadades Neoplasticas (INEN)
- Antiva Biosciences
Organization Involved with Other Experimental Indications (2)